Tuesday 7th July - 3pm BST/ 10am EST
How do we ensure continued patient access to ATMPs & orphan drugs during and after a pandemic?
Exploring the impact on patient access and treatments
How have treatments centers changed their procedures? What will this mean for the future?
How are we working to identify and improve barriers to new payment models?
Implementing a multi-stakeholder approach to ensure robust RWE generation and utilization
How will RWE help fill evidence gaps to payers?
Doug Danison, Senior Vice President, Market Access, Value & Evidence Strategy,
Etienne Jousseaume, Head Market Access Cell& Gene Therapy,
Paolo Morgese, EU Director Market Access & Member Relations,
Alliance for Regenerative Medicine
Michela Gabaldo, Head, Alliance Management & Regulatory Affairs,
Josie Godfrey, Director,
JG Zebra Consulting
Optimising clinical development strategies for gene therapies and orphan drugs as a whole
How do we overcome clinical trial design hurdles?
Exploring alternate clinical trial designs
Engaging patients as early as possible
Building new drug development frameworks (galaxy guide)
Anne Pariser, Director, Office Of Rare Diseases Research, National Center For Advancing Translational Sciences -
Christeen Moburg,Senior Director, Patient Advocacy,
Dr Diego Ardigo, Chair, IRDiRC Therapies Scientific Committee & R&D Rare Diseases Unit Head,
Samantha Parker, SVP & Chief Patient Access Officer,
Virginie Hivert, Therapeutic Development Director,